ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
about
Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple IntegrinsAberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic targetRadiolabeled cyclic RGD peptides as radiotracers for tumor imagingA phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphomaMonitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2.Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.Novel inhibitors in development for hepatocellular carcinoma.FMS-like tyrosine kinase 3 inhibitors: a patent review.Inhibition of the VEGF signalling pathway and glomerular disorders.Linifanib: current status and future potential in cancer therapy.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Dual-acting histone deacetylase-topoisomerase I inhibitors.FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.A New Role for Helicobacter pylori Urease: Contributions to Angiogenesis.X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery.A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategiesOncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers
P2860
Q26801806-035BC3D6-2948-4146-A761-1865C22A9954Q26995561-D4B03747-75B9-4645-804F-3EF33C3E73E2Q28072021-75EB1391-1761-4E49-AA5A-0F901D7B75FDQ33415143-32197828-0FCB-4B8B-893A-5A19A392C8CEQ33817062-B17B414D-7F5C-4AC6-8424-A607B9D37083Q34047994-09B2010A-08F1-4F66-83CA-7E67B6020D2EQ34786090-A472673F-EE44-4AD4-8196-803EB02B790CQ35038725-3E416B80-31DE-49FE-97C4-26A7DA839E1FQ35186102-9631B456-7723-4AD0-B84D-4B1EC2757A80Q37027027-6DB4C20D-D163-46AC-A102-D78B38274249Q37344824-2FCC8534-7ACB-4DF7-A3BE-AEB2D9E593ABQ37725994-570775C6-4EDB-43E3-A634-ED751A1B4A7FQ37842585-5491A1CA-12A4-4C16-824C-6D54BEAEA536Q38284055-D5AB3A4F-366F-4C60-AAE6-F327E8D673B0Q38455525-8F8E99F4-1E1F-4E4F-B5B0-432EB6636A1CQ38498207-32CDA32E-3758-42BC-A80F-9579784E4E13Q38685867-0B879293-C321-44B0-B004-2607CFA86255Q38743040-D43608CC-486C-40BF-A50A-55B605C702CCQ38933836-81F0A0F9-B3B3-43FA-AE81-A7CDBFEA03B8Q38985337-2ACDBEDA-AFDC-4BA5-966E-F27152CD2C3BQ39159726-17E43BBA-FE86-4CAD-8532-A136BADBE510Q39397672-3F75B2A8-3F0A-494C-BA74-17CA99CB91B3Q41258130-DA92566C-E92D-4433-A0D7-7B3AF00CDA77Q42053469-4808F226-2F71-457B-A4C8-FFB092D5E7B9Q42288754-94B09334-4536-4AA5-9BB8-A522B7EE3A7BQ47103190-46D7FD9D-0046-4D73-BC3E-84F6ED66FA62Q52668830-A78DF0A4-D056-42D0-97E3-9BE85EC4165AQ53389797-90D1BE6F-F66E-4109-9052-2C66377810F8Q58739975-0CABA74B-6519-4204-89CD-3EB0C27812E3Q59123158-1F4477CB-CE1D-4403-9EA3-A1338EC7FC52
P2860
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@en
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@nl
type
label
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@en
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@nl
prefLabel
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@en
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@nl
P2093
P2860
P921
P356
P1476
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
@en
P2093
Boon-Cher Goh
Chien-Shing Chen
Daniel H Albert
Jianbiao Zhou
P2860
P2888
P356
10.1186/1756-8722-2-33
P577
2009-07-30T00:00:00Z
P5875
P6179
1006510146